Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
21492180

DOI
10.1111/j.1537-2995.2011.03136.x

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adult; Aged; Antigens, CD34 /blood; Blood Component Removal; Cohort Studies; Cost-Benefit Analysis; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor /administration & dosage; Hematopoietic Stem Cell Mobilization /economics /methods; Hematopoietic Stem Cells /drug effects; Heterocyclic Compounds /administration & dosage /pharmacology; Humans; Lymphoma /blood /therapy; Male; Middle Aged; Multiple Myeloma /blood /therapy; Peripheral Blood Stem Cell Transplantation /economics /methods; Receptors, CXCR4 /antagonists & inhibitors; Retrospective Studies; Salvage Therapy; Time Factors; Transplantation, Autologous; Young Adult

AccessionNumber
22012000231

Date bibliographic record published
12/06/2012